Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025
Autolus Therapeutics (Nasdaq: AUTL) has announced an upcoming R&D Investor Event scheduled for Wednesday, April 23, 2025, at 8:30am EDT / 13:30pm BST in New York City. The event will feature key updates on:
- Clinical pipeline programs and expansion plans for obe-cel
- Initial data from six patients in the CARLYSLE Phase 1 trial for systemic lupus erythematosus (SLE)
- Development plans for expansion in autoimmune diseases
- Progress update on the commercial launch of AUCATZYL®
The presentation will be accessible via webcast on the company's website, with a 90-day replay period available. Interested parties can inquire about in-person attendance through the provided contact.
Autolus Therapeutics (Nasdaq: AUTL) ha annunciato un prossimo Evento per Investitori R&D programmato per mercoledì 23 aprile 2025, alle 8:30 EDT / 13:30 BST a New York City. L'evento presenterà aggiornamenti chiave su:
- Programmi della pipeline clinica e piani di espansione per obe-cel
- Dati iniziali da sei pazienti nel trial CARLYSLE di Fase 1 per il lupus eritematoso sistemico (LES)
- Piani di sviluppo per l'espansione nelle malattie autoimmuni
- Aggiornamento sui progressi del lancio commerciale di AUCATZYL®
La presentazione sarà accessibile tramite webcast sul sito web dell'azienda, con un periodo di riproduzione di 90 giorni disponibile. Le parti interessate possono chiedere informazioni sulla partecipazione in persona attraverso il contatto fornito.
Autolus Therapeutics (Nasdaq: AUTL) ha anunciado un próximo Evento para Inversores en I+D programado para el miércoles 23 de abril de 2025, a las 8:30 a.m. EDT / 13:30 p.m. BST en la ciudad de Nueva York. El evento contará con actualizaciones clave sobre:
- Programas de la cartera clínica y planes de expansión para obe-cel
- Datos iniciales de seis pacientes en el ensayo CARLYSLE de Fase 1 para el lupus eritematoso sistémico (LES)
- Planes de desarrollo para la expansión en enfermedades autoinmunes
- Actualización sobre el lanzamiento comercial de AUCATZYL®
La presentación estará disponible a través de una transmisión en vivo en el sitio web de la empresa, con un período de repetición de 90 días. Las partes interesadas pueden preguntar sobre la asistencia en persona a través del contacto proporcionado.
Autolus Therapeutics (Nasdaq: AUTL)는 2025년 4월 23일 수요일 오전 8시 30분 EDT / 오후 1시 30분 BST에 뉴욕에서 예정된 R&D 투자자 행사를 발표했습니다. 이 행사에서는 다음에 대한 주요 업데이트가 제공됩니다:
- obe-cel의 임상 파이프라인 프로그램 및 확장 계획
- 전신성 홍반 루푸스(LES)에 대한 CARLYSLE 1상 시험에서 6명의 환자에 대한 초기 데이터
- 자가면역 질환에서의 확장 개발 계획
- AUCATZYL®의 상업적 출시 진행 상황 업데이트
프레젠테이션은 회사 웹사이트를 통해 웹캐스트로 접근 가능하며, 90일 재생 기간이 제공됩니다. 관심 있는 분은 제공된 연락처를 통해 대면 참석에 대해 문의할 수 있습니다.
Autolus Therapeutics (Nasdaq: AUTL) a annoncé un prochain Événement Investisseur R&D prévu pour le mercredi 23 avril 2025, à 8h30 EDT / 13h30 BST à New York. L'événement présentera des mises à jour clés sur :
- Les programmes de pipeline clinique et les plans d'expansion pour obe-cel
- Les données initiales de six patients dans l'
- Les plans de développement pour l'expansion dans les maladies auto-immunes
- Mise à jour des progrès sur le lancement commercial d'AUCATZYL®
La présentation sera accessible via un webinaire sur le site web de l'entreprise, avec une période de rediffusion de 90 jours disponible. Les parties intéressées peuvent se renseigner sur la participation en personne via le contact fourni.
Autolus Therapeutics (Nasdaq: AUTL) hat ein bevorstehendes F&E-Investoren-Event angekündigt, das für Mittwoch, den 23. April 2025, um 8:30 Uhr EDT / 13:30 Uhr BST in New York City geplant ist. Die Veranstaltung wird wichtige Updates zu folgenden Themen bieten:
- Klinische Pipeline-Programme und Expansionspläne für obe-cel
- Erste Daten von sechs Patienten aus der CARLYSLE-Phase-1-Studie zu systemischem Lupus erythematodes (SLE)
- Entwicklungspläne zur Expansion bei Autoimmunerkrankungen
- Fortschrittsupdate zum kommerziellen Launch von AUCATZYL®
Die Präsentation wird über einen Webcast auf der Unternehmenswebsite zugänglich sein, mit einer 90-tägigen Wiederholungszeit. Interessierte Parteien können über den bereitgestellten Kontakt Informationen zur persönlichen Teilnahme anfragen.
- None.
- None.
LONDON, April 01, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announced that the Company will host an R&D investor event on Wednesday, April 23, 2025 at 8:30am EDT / 13:30pm BST.
Autolus will present an update on clinical pipeline programs, including plans to expand the obe-cel opportunity. The Company expects to report initial data in six patients from the ongoing CARLYSLE Phase 1 trial in systemic lupus erythematosus (SLE), announce development plans for expansion in autoimmune diseases, and provide a brief update of the ongoing commercial launch of AUCATZYL®.
A webcast of the presentation will be available on the “Events” page in the “Investor Relations & Media” section of the Company’s website at https://www.autolus.com/investor-relations-media/events/. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.
The live event will be held in New York City. To inquire about in-person attendance please email: susan@sanoonan.com.
About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has an FDA approved product, AUCATZYL, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com
Contact:
Amanda Cray
+1 617-967-0207
a.cray@autolus.com
Olivia Manser
+44 7780 471 568
o.manser@autolus.com
FAQ
What will Autolus Therapeutics (AUTL) present at their April 2025 R&D Investor Event?
When and where is the Autolus Therapeutics (AUTL) R&D Investor Event taking place?
How can investors access Autolus Therapeutics' (AUTL) April 2025 R&D presentation?
What clinical trial data will AUTL present at the April 2025 R&D Event?
How long will the AUTL R&D Event presentation replay be available?
